Assessment of coronary artery disease during hospitalization for cancer treatment.
Acute coronary syndrome
Cancer
Cardio-oncology
Cardiotoxicity
Coronary artery disease
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
19
05
2020
accepted:
23
07
2020
pubmed:
4
8
2020
medline:
25
8
2021
entrez:
4
8
2020
Statut:
ppublish
Résumé
With improvement of cancer-specific survival, comorbidities and treatment-related side effects, particularly cardiovascular toxicities, need close attention. The aim of the present study was to evaluate clinical characteristics and outcomes of cancer patients requiring coronary angiography during inpatient care. We performed a retrospective analysis of patients hospitalized between 02/2011 and 02/2018 in our two university hospital cancer centers. From a cohort of 60,676 cancer patients, we identified 153 patients (65.7 ± 11.6 years, 73.2% male), who underwent coronary angiography and were eligible for analysis. These were compared to a control group of 153 non-cancer patients pair-matched with respect to age, sex, and indication for catheterization. Cancer patients presented in 66% with an acute coronary syndrome (ACS). The most prevalent cancer entities were lymphoma (19%) and lung cancer (18.3%). The rate of primary percutaneous coronary interventions (PCI) was significantly lower in the cancer cohort (40.5% vs. 53.6%, p = 0.029), although manifestation of coronary artery disease (CAD) and PCI results were comparable (SYNergy between PCI with TAXus and cardiac surgery (SYNTAX)-score, delta pre- and post-PCI - 9.8 vs. - 8.0, p = 0.2). Mortality was remarkably high in cancer patients (1-year mortality 46% vs. 8% in non-cancer patients, p < 0.001), particularly with troponin-positive ACS (5-year mortality 71%). Strategies to effectively control cardiovascular risks in cancer patients are needed. Additionally, suspected CAD in cancer patients should not prevent prompt diagnostic clarification and optimal revascularization as PCI results in cancer patients are comparable to non-cancer patients and occurrence of troponin-positive ACS leads to a significantly increased risk of mortality.
Sections du résumé
BACKGROUND
BACKGROUND
With improvement of cancer-specific survival, comorbidities and treatment-related side effects, particularly cardiovascular toxicities, need close attention. The aim of the present study was to evaluate clinical characteristics and outcomes of cancer patients requiring coronary angiography during inpatient care.
METHODS
METHODS
We performed a retrospective analysis of patients hospitalized between 02/2011 and 02/2018 in our two university hospital cancer centers. From a cohort of 60,676 cancer patients, we identified 153 patients (65.7 ± 11.6 years, 73.2% male), who underwent coronary angiography and were eligible for analysis. These were compared to a control group of 153 non-cancer patients pair-matched with respect to age, sex, and indication for catheterization.
RESULTS
RESULTS
Cancer patients presented in 66% with an acute coronary syndrome (ACS). The most prevalent cancer entities were lymphoma (19%) and lung cancer (18.3%). The rate of primary percutaneous coronary interventions (PCI) was significantly lower in the cancer cohort (40.5% vs. 53.6%, p = 0.029), although manifestation of coronary artery disease (CAD) and PCI results were comparable (SYNergy between PCI with TAXus and cardiac surgery (SYNTAX)-score, delta pre- and post-PCI - 9.8 vs. - 8.0, p = 0.2). Mortality was remarkably high in cancer patients (1-year mortality 46% vs. 8% in non-cancer patients, p < 0.001), particularly with troponin-positive ACS (5-year mortality 71%).
CONCLUSION
CONCLUSIONS
Strategies to effectively control cardiovascular risks in cancer patients are needed. Additionally, suspected CAD in cancer patients should not prevent prompt diagnostic clarification and optimal revascularization as PCI results in cancer patients are comparable to non-cancer patients and occurrence of troponin-positive ACS leads to a significantly increased risk of mortality.
Identifiants
pubmed: 32743679
doi: 10.1007/s00392-020-01719-5
pii: 10.1007/s00392-020-01719-5
pmc: PMC7862534
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
200-210Références
Int J Cardiol. 2019 Apr 1;280:163-175
pubmed: 30661849
J Natl Cancer Inst. 1993 Jun 16;85(12):979-87
pubmed: 8496983
J Thorac Dis. 2018 Dec;10(Suppl 35):S4386-S4390
pubmed: 30701105
J Am Coll Cardiol. 2017 Nov 14;70(20):2536-2551
pubmed: 29145954
Circulation. 2014 Dec 23;130(25):2354-94
pubmed: 25249586
Coron Artery Dis. 2017 Jan;28(1):5-10
pubmed: 27622995
N Engl J Med. 2009 Dec 10;361(24):2342-52
pubmed: 19966341
Am J Cardiovasc Drugs. 2017 Feb;17(1):61-71
pubmed: 27738920
Eur Heart J Acute Cardiovasc Care. 2018 Oct;7(7):631-638
pubmed: 28593789
Cancer. 1974 Feb;33(2):568-73
pubmed: 4591273
Eur J Prev Cardiol. 2018 Mar;25(5):482-494
pubmed: 29376753
Circulation. 2016 Sep 6;134(10):e123-55
pubmed: 27026020
N Engl J Med. 2010 Dec 23;363(26):2499-510
pubmed: 21128814
Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1125
pubmed: 26675199
J Clin Oncol. 2016 Feb 20;34(6):611-35
pubmed: 26644543
Pol Arch Intern Med. 2018 Apr 30;128(4):244-253
pubmed: 29708956
Tex Heart Inst J. 2011;38(3):259-60
pubmed: 21720465
JAMA Oncol. 2015 Dec;1(9):1303-10
pubmed: 26448610
J Am Coll Cardiol. 2014 Nov 4;64(18):1929-49
pubmed: 25077860
Ann Oncol. 2002 May;13(5):710-5
pubmed: 12075738
Circulation. 2004 Jun 8;109(22):2749-54
pubmed: 15148277
Eur Heart J. 2019 Jan 7;40(2):87-165
pubmed: 30165437
Eur J Med Res. 2019 Jan 3;24(1):1
pubmed: 30606260
N Engl J Med. 2013 Oct 10;369(15):1406-15
pubmed: 23991658
Mayo Clin Proc. 2016 Dec;91(12):1675-1677
pubmed: 27916153
Eur J Heart Fail. 2016 Dec;18(12):1524-1534
pubmed: 27910284
Cancer. 2020 May 15;126(10):2225-2249
pubmed: 32162336
J Am Heart Assoc. 2017 Aug 10;6(8):
pubmed: 28862931
N Engl J Med. 2009 Mar 5;360(10):961-72
pubmed: 19228612
N Engl J Med. 2013 Aug 29;369(9):799-808
pubmed: 23808982
JAMA Cardiol. 2016 Dec 1;1(9):1066-1072
pubmed: 27541948
Neth Heart J. 2018 Sep;26(9):454-460
pubmed: 30039381
J Am Coll Cardiol. 2012 Jun 12;59(24):2165-74
pubmed: 22483327
ESC Heart Fail. 2020 Apr;7(2):423-433
pubmed: 32069386
Clin Cardiol. 2012;35(7):443-50
pubmed: 22588943
Mayo Clin Proc. 2016 Jan;91(1):81-3
pubmed: 26602599
J Am Coll Cardiol. 2000 Aug;36(2):517-22
pubmed: 10933366
Circulation. 2011 Jun 14;123(23):2736-47
pubmed: 21670242
Eur Heart J. 2007 Nov;28(22):2706-13
pubmed: 17901079
Eur Heart J. 2000 Sep;21(18):1502-13
pubmed: 10973764
N Engl J Med. 2003 Jul 10;349(2):146-53
pubmed: 12853587
Clin Res Cardiol. 2020 Oct;109(10):1197-1222
pubmed: 32405737
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
J Thorac Dis. 2018 Dec;10(Suppl 35):S4282-S4295
pubmed: 30701097
Eur J Heart Fail. 2020 Feb;22(2):350-361
pubmed: 31721381
Mayo Clin Proc. 2016 Dec;91(12):1680-1692
pubmed: 27916154
Eur Heart J. 2019 Jun 7;40(22):1790-1800
pubmed: 30500952
Curr Oncol. 2017 Aug;24(4):256-261
pubmed: 28874894